Philippines Business News API

{
    "totalArticles": 286652,
    "articles": [
        {
            "id": "cdef6caed25a182f490beecb5ecad568",
            "title": "Vietnam Tourism Innovations in the Da Nang, Hoi An and Ba Na Hills Triangle are Leading a New Era for Southeast Asian Travel",
            "description": "Explore the 2026 transformation of Vietnam's tourism, as Da Nang, Hoi An, and Ba Na Hills redefine Southeast Asian travel through innovation and infrastructure.",
            "content": "The landscape of regional exploration is being significantly reshaped by the Vietnam Tourism Transformation occurring throughout the central corridors of the nation. As of March 2026, the trio of Da Nang, Hoi An, and Ba Na Hills has emerged as a prim... [6117 chars]",
            "url": "https://www.travelandtourworld.com/news/article/vietnam-tourism-innovations-in-the-da-nang-hoi-an-and-ba-na-hills-triangle-are-leading-a-new-era-for-southeast-asian-travel/",
            "image": "https://www.travelandtourworld.com/wp-content/uploads/2026/03/Hanoi-1.jpg",
            "publishedAt": "2026-03-28T20:12:14Z",
            "lang": "en",
            "source": {
                "id": "1cbffab9ade94d830ac7fbb7c9713f30",
                "name": "Travel And Tour World",
                "url": "https://www.travelandtourworld.com"
            }
        },
        {
            "id": "3e1614cc21838392cb002a6a86e991b0",
            "title": "Steel Power Male Enhancement Claims Evaluated: Complete SteelPower Performance Report for Men",
            "description": "A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, pricing structure, and what the SteelPower formula label discloses for men",
            "content": "A 2026 report outlining Steel Power ingredient research, male enhancement supplement positioning, performance claim context, pricing structure, and what the SteelPower formula label discloses for men\nAurora, CO, March 28, 2026 (GLOBE NEWSWIRE) -- The... [26259 chars]",
            "url": "https://www.manilatimes.net/2026/03/29/tmt-newswire/globenewswire/steel-power-male-enhancement-claims-evaluated-complete-steelpower-performance-report-for-men/2309920",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/03/29/992721.png",
            "publishedAt": "2026-03-28T19:28:32Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        },
        {
            "id": "290a548bb2480783fa1ad0ffad58dc02",
            "title": "MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting",
            "description": "Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to 32% of patients achieving HiSCR100 An analysis of different hallmark lesions of HS shows that up to 25% of patients achieved inflammatory remission at Week 40, defined as a 100% reduction in abscesses (A100), nodules (N100) and draining tunnels (DT100)Patients treated with SLK also showed substantial improvements in HiSQOL items at week 40 versus baseline, ranging from 41% (pain), to 54% (walking, getting dressed) to 62% (down or depressed)Up to 43% of patients achieved an at least 3-point improvement from baseline in the worst skin pain NRS, while 65% of patients achieved an improvement of at least 4 points from baseline in DLQINo new safety signals were detected in the VELA trials to-dateDetailed results will be presented at the S034 Late-Breaking Research: Session 2 by Prof. Alexa Kimball, Investigator at Beth Israel Deaconess Medical Center, and Professor of Dermatology at Harvard Medical School, at the 2026 AAD Annual Meeting on March 28, 2026ZUG, Switzerland, March 28, 2026 - MoonLake Immunotherapeutics (NASDAQ: MLTX) (MoonLake or the Company), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announces long-term Week 40 results of the Phase 3 VELA-1 and VELA-2 clinical trials of its registrational global program in patients with moderate-to-severe HS and confirms the presentation of the data at the 2026 American Academy of Dermatology (AAD) Annual Meeting later today.",
            "content": "Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab (SLK) achieving HiSCR75 and up to... [27368 chars]",
            "url": "https://www.manilatimes.net/2026/03/29/tmt-newswire/globenewswire/moonlake-announces-week-40-results-from-its-phase-3-clinical-trials-of-sonelokimab-in-hidradenitis-suppurativa-at-the-2026-aad-annual-meeting/2309918",
            "image": "https://www.manilatimes.net/manilatimes/uploads/images/2026/03/29/992719.png",
            "publishedAt": "2026-03-28T19:08:27Z",
            "lang": "en",
            "source": {
                "id": "e3ad8bbf7dbe3c3defc56a8393455066",
                "name": "The Manila Times",
                "url": "https://www.manilatimes.net"
            }
        }
    ]
}